Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_7144



Chemical Information
Antiviral agent IDDrugRepV_7144
Antiviral agent name4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide
IUPAC Name4-{3-[4-(benzyloxy)phenyl]-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-1-yl}benzene-1-sulfonamide PubChem
SMILES (canonical)[H]N([H])S(=O)(=O)C1=CC=C(C=C1)N1N=C(CC1C1=CC=C(C)C=C1)C1=CC=C(OCC2=CC=CC=C2)C=C1 PubChem
Molecular FormulaC29H27N3O3S PubChem
Molecular Weight (g/mol)497.61 PubChem
InChlInChI=1/C29H27N3O3S/c1-21-7-9-24(10-8-21)29-19-28(31-32(29)25-13-17-27(18-14-25)36(30,33)34)23-11-15-26(16-12-23)35-20-22-5-3-2-4-6-22/h2-18,29H,19-20H2,1H3,(H2,30,33,34) PubChem
Structural Information
  
Clinical Information
Biological Information
Secondary Indication Yellow fever virus (YFV) NA 17DWorld Health OrganisationCDC
Secondary Indication (Approaches)Experimental
Secondary Indication (Methods)In-vitro
Secondary Indication (Model system) [cell lines/ animal models]BHK-21
Secondary Indication (Mode of viral infection)Adsorption
Secondary Indication (Viral titer)0.01 MOI
Secondary Indication (Mode of drug delivery) Culture
Secondary Indication (Drug concentration)1.8 ± 0.2 μM
Secondary Indication (Cell based assay)MTT assay
Secondary Indication (Change)Decrease
Secondary Indication (Type of Inhibition) EC50 [ 50 % ]
Secondary Indication (Cytotoxicity)36 ± 4 μM
ReferenceFioravanti R, Desideri N, Carta A, Atzori EM, Delogu I, Collu G, Loddo R..Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation..Eur J Med Chem. 2017 Dec 1;141:15-25. doi: 10.1016/j.ejmech.2017.09.060. Epub 2017 Sep 28. PMID:29028528 PubMed
Comment6-Azauridine, ribavirin, 2'-C-methyl-guanosin (NM108), efavirenz (EFV), pleconaril, acyclovir (ACG), and mycophenolic acid (M5255) were employed as reference inhibitors.